In a significant ruling, the European Union’s ambitions to enhance its regulatory oversight on global mergers faced a challenge after the EU’s General Court determined that Illumina Inc.’s $7 billion acquisition of cancer-detection company Grail Inc. was wrongfully examined by European antitrust authorities. The judgment has raised questions about the limits of the EU’s jurisdiction in scrutinizing mergers that may not meet the traditional thresholds for intervention but could still impact competition.
The case pivots on the EU’s use of Article 22 of the EU Merger Regulation, which allows member states to refer mergers to the European Commission for review, even if they fall below the national and European notification thresholds. The EU’s General Court found that this approach was misapplied in the Illumina-Grail case. According to the court, the referral mechanism should not have been invoked, thereby curtailing the European Commission’s attempt to investigate the merger under its existing formal procedures.
The ruling could significantly reshape the European Commission’s strategy in monitoring mergers, pushing regulatory bodies to reconsider the scope and methodology of their investigations. This decision underscores the challenges faced by regulators in addressing the complexities of modern mergers in a globalized economy. Legal experts suggest that the ramifications of this judgment could influence future cases and potentially limit the Commission’s reach.
The full details of the ruling can be found on Bloomberg Law.